FindTrial
Sign In

Using Optical Coherence Tomography, which is a scan used in ophthalmology for detecting side effects of a drug- Hydroxychloroquine which is used in systemic diseases like Rheumatoid Arthritis which can cause permanent vision loss; before actual vision loss occurs.

Role of Optical Coherence Tomography in early detection of Hydroxychloroquine Retinopathy preceding visual field defects.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/01/022628
Enrollment
150
Registered
2020-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H358- Other specified retinal disorders

Interventions

None listed

Sponsors

Dr Premjith Muraleedharan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients using Tablet Hydroxychloroquine for more than 12 +/- 3 months

Exclusion criteria

Exclusion criteria: 1. Patients with any ocular infection, or any other ocular disease like glaucoma, optic nerve and retinal diseases, uveitis, previous ocular surgeries, refractive errors and media opacity (Refractive error greater than +/- 6D sphere or +/- 3D cylindrical) 2. Patients with renal/ liver dysfunction. 3. Patients on concomitant Tamoxifen therapy. 4. Parents not willing to participate.

Design outcomes

Primary

MeasureTime frame
Detection of reduction in ILM-RPE thickness and GCC thickness (by SD-OCT) before perimetric loss occurs (HFA 30-2)Timepoint: Same day/one day—

Secondary

MeasureTime frame
Early detection of Hydroxychloroquine retinopathyTimepoint: Same day/one day—

Countries

India

Contacts

Public ContactDR VIJAYA PAI H

Kasturba Medical College, Manipal

pai.vijaya@manipal.edu7025892166

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026